1. Home
  2. CYTK vs PEN Comparison

CYTK vs PEN Comparison

Compare CYTK & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

SELL

Current Price

$54.70

Market Cap

10.7B

Sector

Health Care

ML Signal

SELL

Logo Penumbra Inc.

PEN

Penumbra Inc.

SELL

Current Price

$320.85

Market Cap

12.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CYTK
PEN
Founded
1997
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
12.6B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
CYTK
PEN
Price
$54.70
$320.85
Analyst Decision
Buy
Hold
Analyst Count
22
17
Target Price
$107.39
★ $362.54
AVG Volume (30 Days)
★ 1.6M
405.6K
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1155.56
EPS
N/A
★ 2.77
Revenue
$13,368,000.00
★ $1,403,665,000.00
Revenue This Year
$79.67
$14.38
Revenue Next Year
$172.23
$12.44
P/E Ratio
★ N/A
$116.41
Revenue Growth
N/A
★ 17.50
52 Week Low
$58.25
$259.14
52 Week High
$88.31
$362.41

Technical Indicators

Market Signals
Indicator
CYTK
PEN
Relative Strength Index (RSI) 52.28 53.01
Support Level $63.96 $321.10
Resistance Level $66.93 $324.56
Average True Range (ATR) 2.04 2.49
MACD 0.50 -0.20
Stochastic Oscillator 86.71 66.09

Price Performance

Historical Comparison
CYTK
PEN

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About PEN Penumbra Inc.

Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Share on Social Networks: